Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 19 crawled time : 07:00 save search
GOGL – First Quarter 2022 Results
Published: 2022-05-19 (Crawled : 07:00) - goldenocean.bm
GOGL | $13.05 -0.31% -0.31% 960K
|
Transportation
|
| O: -2.31%
H: 10.81%
C: 8.24%
results
EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate
Published: 2022-05-19 (Crawled : 07:00) - biospace.com/
DVAX | $11.35 -0.7% -0.7% 2.2M
|
Health Technology
|
| O: 1.38%
H: 17.99%
C: 16.95%
covid-19 vaccine ema application authorization
High Protein-Based Food Market - 37% of Growth to Originate from North America | Evolving Opportunities with Abbott Laboratories & Clif Bar & Co. | Technavio
Published: 2022-05-19 (Crawled : 07:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.42%
H: 3.46%
C: 3.46%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -2.97%
H: 0.0%
C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
america food growth market
Addex Announces Participation in the H.C. Wainwright Global Investment Conference
Published: 2022-05-19 (Crawled : 07:00) - biospace.com/
ADXN | $24.01 9.14% 8.37% 19K
|
Health Technology
|
| O: -0.78%
H: 0.0%
C: 0.0%
conference
Fusion Fuel Green and Toshiba Energy Systems and Solutions Corporation Enter into Green Hydrogen MOU
Published: 2022-05-19 (Crawled : 07:00) - globenewswire.com
HTOO | $1.32 1.54% 1.52% 54K
|
|
| O: -1.62%
H: 4.36%
C: -1.3%
solutions energy corporation hydrogen
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022
Published: 2022-05-19 (Crawled : 07:00) - biospace.com/
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: -4.32%
H: 14.03%
C: 9.75%
bion-1301 nephropathy preclinical renal trial therapeutics pre-clinical phase 1 igan
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022
Published: 2022-05-19 (Crawled : 07:00) - globenewswire.com
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: -4.32%
H: 14.03%
C: 9.75%
bion-1301 nephropathy preclinical renal trial therapeutics pre-clinical phase 1 igan
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
Published: 2022-05-19 (Crawled : 07:00) - biospace.com/
EVO | News | $7.19 -0.69% -0.7% 27K
|
Manufacturing
|
| O: -0.71%
H: 4.69%
C: 3.9%
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.